TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Consensus Recommendation of "Hold" by Analysts

Key Points

• Analysts hold a consensus “Hold” rating on TriSalus Life Sciences, with three buys, one hold and one sell among five analysts. The average 12-month price target is $8.67, versus a recent share price of $4.73.
• Recent analyst actions were mixed: Lake Street lowered its price target to $8 while maintaining a buy rating, HC Wainwright initiated coverage with a buy rating and an $11 target, and Weiss maintained a sell rating.
• TriSalus reported quarterly revenue of $11.41 million, above the $10.27 million estimate, while adjusted earnings matched expectations at a loss of $0.16 per share. Institutional ownership remains limited at 2.58%.

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) have been given a consensus recommendation of "Hold" by the five ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $8.6667.

Several research firms recently commented on TLSI. Lake Street Capital dropped their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen raised shares of TriSalus Life Sciences from a "sell" rating to a "hold" rating in a report on Sunday, August 23rd. Weiss Ratings reissued a "sell (e+)" rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Finally, HC Wainwright began coverage on shares of TriSalus Life Sciences in a report on Wednesday. They issued a "buy" rating and a $11.00 price objective for the company.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Cura Wealth Advisors LLC purchased a new stake in shares of TriSalus Life Sciences during the second quarter worth about $36,000. JPMorgan Chase & Co. lifted its position in TriSalus Life Sciences by 35,804.8% during the second quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company's stock valued at $41,000 after buying an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in TriSalus Life Sciences in the second quarter worth about $47,000. Invesco Ltd. purchased a new stake in shares of TriSalus Life Sciences in the fourth quarter worth $72,000. Finally, Abel Hall LLC bought a new position in shares of TriSalus Life Sciences in the fourth quarter worth approximately $73,000. 2.58% of the stock is currently owned by institutional investors.

TriSalus Life Sciences Stock Performance

Shares of TriSalus Life Sciences stock opened at $4.73 on Wednesday. The business has a 50 day moving average price of $4.75 and a 200-day moving average price of $4.33. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95. The company has a market cap of $291.25 million, a PE ratio of -3.64 and a beta of 0.44. The company has a quick ratio of 4.97, a current ratio of 5.35 and a debt-to-equity ratio of 5.05.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, meeting the consensus estimate of ($0.16). The firm had revenue of $11.41 million during the quarter, compared to analysts' expectations of $10.27 million.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company's pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.